Int J Hyper:加热化疗药物或可改善膀胱癌疗法

2016-05-18 生物谷 生物谷

日前,来自西班牙的研究人员发现,加热名为丝裂霉素C的化疗药物或可完全改变该药物的功效,此前丝裂霉素C用来治疗膀胱癌。

图片摘自:livescience.com

日前,来自西班牙的研究人员发现,加热名为丝裂霉素C的化疗药物或可完全改变该药物的功效,此前丝裂霉素C用来治疗膀胱癌,相关研究刊登于国际杂志the International Journal of Hyperthermia上。

这项研究发现是科学家们花费四年半时间的成果,他们设计的再循环高温膀胱内化学疗法(Recirculant hyperthermic IntraVEsical chemotherapy treatment,HIVEC)主要包括加热丝裂霉素C溶液,随后用水稀释直至温度达到43,载将药物溶液运输至膀胱中,在稳定压力下该药物每分钟可以循环200毫升,同时膀胱内的温度可以维持60分钟。40位膀胱癌患者参与到了这项研究计划中,他们被分为两组,其中一组在进行膀胱切除术前接受这种新型疗法(HIVEC),而另外一组在进行膀胱切除后接受该疗法。

其中97%的患者都可以完成整个HIVEC治疗过程,而且大部分的参与者对疗法反应良好,均表现出了较低的复发率,此外患者机体出现的副作用程度较低,而且对治疗计划的影响较小。大部分的膀胱癌患者都会通过内镜手术切除或肿瘤组织的切除来进行癌症治疗,然而有些患者则需要后期治疗,其中就包括膀胱周围的循环药物疗法,一旦疗法失败可选择的疗法就变得非常少了,除非移除膀胱。

常见的卡介苗疗法(Bacillus Calmette–Guérin,BCG)是一种非常有效的治疗非肌肉浸润性膀胱肿瘤的疗法,而丝裂霉素C效力并不如卡介苗,但研究者认为,对丝裂霉素C药物溶液进行加热可以部分增加药物的效力,而这或许归因于高温增加了药物的可溶性,同时部分也因为膀胱粘膜组织通透性的增加。

随后研究人员模拟了每位患者接受HIVEC疗法的成本节约情况,三年后患者大约可节约687欧元;更让研究者不可意思的是,当他们利用HIVEC疗法来治疗某些患者时,在大部分患者机体中肿瘤完全消失了,而且在接下来的几年里肿瘤并没有复发;这或许就表明,对于某些患者而言,HIVEC疗法或许是一种低侵入性的可替代疗法。

原始出处:

Alejandro Sousaa,et al.Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate–high-risk non-muscle-invasive bladder cancer.the International Journal of Hyperthermia.doi:10.3109/02656736.2016.1142618

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1726098, encodeId=2a2b1e26098af, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 09 03:00:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138150, encodeId=bd2313815038, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:20:02 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506699, encodeId=18bd15066994d, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581736, encodeId=09b21581e36ad, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86575, encodeId=4946865e5e4, content=是这样的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86576, encodeId=638f865e684, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-12-09 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1726098, encodeId=2a2b1e26098af, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 09 03:00:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138150, encodeId=bd2313815038, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:20:02 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506699, encodeId=18bd15066994d, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581736, encodeId=09b21581e36ad, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86575, encodeId=4946865e5e4, content=是这样的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86576, encodeId=638f865e684, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1726098, encodeId=2a2b1e26098af, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 09 03:00:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138150, encodeId=bd2313815038, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:20:02 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506699, encodeId=18bd15066994d, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581736, encodeId=09b21581e36ad, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86575, encodeId=4946865e5e4, content=是这样的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86576, encodeId=638f865e684, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1726098, encodeId=2a2b1e26098af, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 09 03:00:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138150, encodeId=bd2313815038, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:20:02 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506699, encodeId=18bd15066994d, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581736, encodeId=09b21581e36ad, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86575, encodeId=4946865e5e4, content=是这样的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86576, encodeId=638f865e684, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1726098, encodeId=2a2b1e26098af, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 09 03:00:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138150, encodeId=bd2313815038, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:20:02 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506699, encodeId=18bd15066994d, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581736, encodeId=09b21581e36ad, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86575, encodeId=4946865e5e4, content=是这样的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86576, encodeId=638f865e684, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-19 milkshark

    是这样的

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1726098, encodeId=2a2b1e26098af, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 09 03:00:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138150, encodeId=bd2313815038, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:20:02 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506699, encodeId=18bd15066994d, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581736, encodeId=09b21581e36ad, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Fri May 20 00:00:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86575, encodeId=4946865e5e4, content=是这样的, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86576, encodeId=638f865e684, content=值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:49:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-19 milkshark

    值得收藏

    0

相关资讯

J Urology:术前心理健康降低术后并发症风险

手术前病人的心理健康会影响术后的结果。对局部晚期膀胱癌患者进行膀胱切除或根治性膀胱切除术(RC)是一种有效的治疗方式,但术后并发症竟高达66%!有研究表明,患者对心理健康自我评价更低,那么其术后30天内并发症风险更高!先前有研究表明,患者基线心理健康越差,术后并发症可能会更多更严重,可能是因为免疫反应受损与更高水平的压力导致的。这可能会延迟伤口愈合,降低术后抗感染能力的能力。尽管身心整体健康的自我

王东:机器人辅助腹腔镜膀胱癌根治回肠原位新膀胱术

新年伊始,2016年2月16日,四川省人民医院机器人手术再传捷报!泌尿专业王东主任医师团队,借助达芬奇机器人手术系统,为一位89岁高龄男性患者成功实施了膀胱根治性切除+回肠原位新膀胱术,耗时仅3小时35分钟,出血量不足80mL。 该患者因高龄始终未能接受根治性治疗,曾多次手术多次复发并多处就医,历经痛苦,后几经辗转赶赴四川省人民医院向机器人团队求助。在王东主任医师、刘竞主治医师、卜司元博

BMJ:2型糖尿病患者服用吡格列酮增加膀胱癌风险

该研究的目的是确定是否吡格列酮与其它抗糖尿病药物相比,是否增加了2型糖尿病患者的膀胱癌的风险。原始出处:Marco Tuccori,Kristian B Filion,Hui Yin,et al.Pioglitazone use and risk of bladder cancer,BMJ,2016.3.31http://www.bmj.com/content/352/bmj.i1541

BMC Cancer:代谢综合征会增加膀胱癌风险!

全球范围内代谢综合征(MetS)逐渐被推到风口浪尖,且认为其会导致几种癌症风险增加,比如膀胱尿路上皮癌(UCB) 。研究者进行了一项研究,评估MetS和UCB的关系。研究者对2003-2014年间意大利的690例癌症患者和665名非癌症匹配患者进行了一项病例对照研究。MetS至少应符合以下3种:腹部肥胖、高胆固醇血症、高血压和糖尿病。多因素Logistic回归模型估计校正潜在混杂因素后的MetS和

分子分型时代,膀胱癌和乳腺癌竟然是一种疾病?

随着人类基因组的面纱逐渐被揭开,分子和基因逐渐取代细胞和组织成为癌症具体分型的依据。最近,北卡罗来纳大学教堂山分校的研究人员在JCI Insight杂志上发表的一项研究结果表明,膀胱癌的一种新亚型与某些类型乳腺癌的分子特征类似。 膀胱癌占美国所有新发癌症的5%左右,是男性第四大常见肿瘤,在女性中则发病率较低。预计在2016年,将有76960名美国人发现自己患上膀胱癌,大约16390名患者

膀胱癌新药或将问世 填补30年来治疗性药物的空白

近日,来自夏威夷大学癌症中心进行的一项膀胱癌药物临床试验已经越来越接近FDA的批准标准了,这种名为白介素15超拮抗剂复合物(ALT-803)的新型药物可以同卡介苗结合,有望有效治疗非肌层浸润性的膀胱癌患者,而非肌层浸润性膀胱癌是目前最为常见的一种膀胱癌。 研究者Charles Rosser表示,上一次FDA批准膀胱癌药物还是几乎20年前的事儿了,目前膀胱癌疗法并没有太大进展,自从上世纪80年代